Nephrotic SyndromeGRANT GALLIMORE, MD, MAJ, USAF, MC
NEPHROLOGY CHIEF, KEESLER MEDICAL CENTER
Overviewo History and terminology
o Major causes of nephrotic syndrome and prevalence
o Patient presentation, history and exam
o Laboratory and imaging based on potential etiology
o Selected pathology and microscopy
o Complications and management
History and Terminology
o Nephrotic was coined in 1905 by Friedrich von Müller, a distinguished German Pathologist
o The term nephrotic syndrome is attributed to Louis Leiter of the University of Chicago, using the term in a widely read review in 1930
o Percutaneous renal biopsy was introduced in 1951, resulting in description of many distinct disease entities
Glassock RJ, Fervenza FC, Hebert L, Cameron JS. Nephrotic syndrome redux. Nephrology Dialysis Transplantation. 2014;30(1):12–7.
History and Terminology
o Berman and Schreiner 1958 biopsy series threshold of 3.5g/24h was determined
o All patients had hypoalbuminemia and oval fat bodies in urine
o Edema was absent in 27% and hyperlipidemia absent in 25%
Glassock RJ, Fervenza FC, Hebert L, Cameron JS. Nephrotic syndrome redux. Nephrology Dialysis Transplantation. 2014;30(1):12–7.
History and Terminologyo Definition should be based on 24h urine excretion of protein rather than albumin, although 60-90% of proteinuria should be albumin
o Many conditions can give rise to nephrotic range proteinuria but not to nephrotic syndrome
o With preserved albumin, responsible lesions are likely to result from secondary processes like hyperfiltration, obesity, nephron loss
o For example, the majority of African Americans with FSGS have nephrotic-range proteinuria but not nephrotic syndrome
Glassock RJ, Fervenza FC, Hebert L, Cameron JS. Nephrotic syndrome redux. Nephrology Dialysis Transplantation. 2014;30(1):12–7.
Glassock RJ, Fervenza FC, Hebert L, Cameron JS. Nephrotic syndrome redux. Nephrology Dialysis Transplantation. 2014;30(1):12–7.
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Sara Conti, Norberto Perico, et al. Early and late scanning electron microscopy findings in diabetic kidney disease. Scientific Reports 8, Article number: 4909 (2018) https://doi.org/10.1038/s41598-018-23244-2
Sara Conti, Norberto Perico, et al. Early and late scanning electron microscopy findings in diabetic kidney disease. Scientific Reports 8, Article number: 4909 (2018) https://doi.org/10.1038/s41598-018-23244-2
Figure 3
American Journal of Kidney Diseases 2015 66, 376-377DOI: (10.1053/j.ajkd.2015.04.006)
Copyright © 2015 National Kidney Foundation, Inc. Terms and Conditions
Patient Historyo Wide spectrum varying from asymptomatic to life-threatening disease
o The following historical elements may be relevant:
oSystemic disease o SLE, RA, Crohn’s, DM, HTN, obesity, nephron loss, frequent UTI
o Family history o FSGS, complement disorders
o Medications o NSAIDs, interferon, bisphosphonates
o History of malignancy o Breast, lung, gastrointestinal, lymphoma
o History of infectiono HIV, Hepatitis B or C, syphilis, malaria
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Examo Edema is often periorbital in the morning (no orthopnea)
o This is in contrast to heart failure (pulmonary congestion producing orthopnea) and cirrhosis (diaphragmatic pressure from ascites)
o Massive weight gain is common, with fluid overload including ascites, pleural effusions, abdominal and genital edema
o Muehrcke lines and xanthelasma may be seen
o Palpable purpura in vasculitis, SLE, cyroglobulinemia
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Parvovirus
Metabolic, Autoimmune, Infectious, Neoplastic, Drugs
Laboratory
o Consider serology for Hepatitis B (MN) and C (MPGN), HIV (FSGS)
o Low C3/C4 may be seen in SLE, MPGN, infection-associated, dense deposit disease, HUS
o ANA to screen SLE as a cause of membranous
o RF may be positive due to RA (MN, amyloid) or cryoglobulinemia
o SPEP and serum free light chains may reveal paraprotein-associated disease whether myeloma, amyloidosis, or others
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Imaging
o Ultrasound scanning to ensure 2 kidneys, rule out obstruction or anatomic abnormalities
o Large kidneys (>14cm) may suggest diabetic nephropathy, amyloid disease, HIV, acute severe GN, or AIN
o Small kidneys (<9cm) and/or cortical thinning should limit enthusiasm for biopsy or aggressive immunosuppression
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Figure 2
American Journal of Kidney Diseases 2015 66, 376-377DOI: (10.1053/j.ajkd.2015.04.006)
Copyright © 2015 National Kidney Foundation, Inc. Terms and Conditions
Couser WG. Primary Membranous Nephropathy. CJASN June 2017, 12 (6) 983-997; DOI: https://doi.org/10.2215/CJN.1176111
Beck LH et al. N Engl J Med 2009; 361: 11-21.
Membranous Nephropathy
Focal Segmental Glomerulsclerosis [Internet]. [cited 2019 Jul 5]. Available from https://unckidneycenter.org/kidneyhealthlibrary/glomerular-disease/focal-segmental-glomerulosclerosis-fsgs/
FSGS light microscopy patterns
Complications and Management
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Edema formation
o Overfill is actually much more common than underfill
o This seems to be related to activation of the epithelial sodium channel (ENaC) by proteolytic enzymes in tubular lumen
o Leads to increased blood volume, RAAS suppression, tendency to hypertension
o Increased blood volume with low oncotic pressure leads to transudation of fluid into interstitium
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Edema formation
o The argument for overfill theoryo Individuals lacking serum albumin often do not have sodium retention
o During recovery, natriuresis occurs prior to improvement in hypoalbuminemia
o IV albumin does not consistently improve natriuresis
o Studies with radioactive albumin have demonstrated low plasma and blood volumes in as few as 2% of cases
o Adrenalectomized rats with nephrotic syndrome have sodium retention
o Proteases such as plasminogen have been shown to activate ENAC
Ray, E. C., Rondon-Berrios, H., Boyd, C. R., & Kleyman, T. R. (2015). Sodium Retention and Volume Expansion in Nephrotic Syndrome: Implications for Hypertension. Advances in Chronic Kidney Disease, 22(3), 179-184. doi:10.1053/j.ackd.2014.11.006
Treatment of edema
o Diuretic efficacy is likely to be impairedo Transport from peritubular capillaries requires protein binding
o Increased protein binding in tubular lumen limits access to transporters
o Gastrointestinal absorption may be limited
o Ways to overcome diuretic resistanceo Use of IV therapy
o Use of thiazide in addition to loop diuretic with close monitoring
o Addition of amiloride (ENaC highly relevant to pathophysiology)
o Consideration of IV albumin
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Use of IV therapy
Addition of thiazide
Addition of amiloride
Use of albumin
Response to hypoalbuminemia
o Increased protein synthesis is not discriminating, as the synthesis of many proteins other than albumin is upregulated
o This includes large molecular weight proteins that are not filtered and may actually increase in concentration
o This has implications for both hyperlipidemia and hypercoagulability
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Metabolic complications
o Hyperlipidemiao Xanthelasmas may have rapid onset
o Raises concern for cardiovascular risk
o Many nephrotic patients will also develop hypertension, uremia, making it difficult to isolate the cardiovascular effects of hyperlipidemia
o Approximately fivefold cardiovascular risk is now accepted (except MCD)
o While beneficial effect of statins in nephrotic syndrome is not proven prospectively, they are generally indicated based on cardiovascular risk
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Metabolic complications
o Hypercoagulabilityo Thromboembolism occurs in up to 10% of nephrotic adults
o Abnormal levels of multiple coagulation proteins
o Enhanced platelet aggregation
o Immobility, hemoconcentration, incident infections
o Highest risk in membranous nephropathy
o Higher risk in patients with albumin <2g/dL
o Renal vein thrombosis in 10-50% (if sought systematically)
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Infectious risk
o Large fluid collections, fragile skin, and dilution of local humoral immune factors all play a role
o Loss of IgG, complement factor B, zinc and transferrin in urine
o Neutrophil phagocytic function is impaired
o Primary peritonitis due to pneumococci is characteristic in children. β-hemolytic streptococci and gram-negatives may also be causative
o Cellulitis by β-hemolytic streptococci is also common
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Treatment
o Treatment of hypercoagulabilityo Risk for thrombotic events increases with degree of hypoalbuminemia
o Full-dose anticoagulation (low-molecular-weight heparin or warfarin) should be strongly considered for albumin <2g/dL
o Treatment of infection o ESR is not helpful, but CRP may raise suspicion
o Regimen should include coverage for pneumococcus
o If repeated infections occur, measure immunoglobulins
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Chronic kidney disease
o Progression to CKD is strongly associated with degree of proteinuriao Uncommon progression if proteinuria <2g/day
o Marked risk for progression if proteinuria >5g/day
o Severe proteinuria identifies glomerular injury, but experimental and clinical evidence suggests proteinuria is harmful to tubulointerstitium
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Treatment
o Preventing CKD progressiono Minimize proteinuria and control blood pressureo Consider ACE/ARB as well as nondihydropyridine calcium channel blockers
o Low dose aldosterone antagonist may overcome aldosterone breakthrough
o Lifestyle modification including sodium restriction, weight normalization
o Avoid monotherapy with dihydropyridine calcium channel blocker due to risk for afferent arteriolar dilatation, worsened proteinuria and progression
o Avoid nephrotoxic agents
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Immunosuppression
o Primary drugs used depending on indication includeo Corticosteroids
o Cyclophosphamide
o Mycophenolate mofetil and azathioprine
o Calcineurin inhibitors (cyclosporine, tacrolimus)
o Rituximab
Floege J, Feehaly J. Introduction to Glomerular Disease. In: Feehally J, Floege Jurgen, Tonelli M, Johnson RJ. Comprehensive clinical nephrology. Edinburgh: Elsevier; 2019. p. 184-98
Questions?